Vertex Pharmaceuticals Incorporated (VIE:VRTX)

Market Cap	84.58B
Revenue (ttm)	9.72B
Net Income (ttm)	3.10B
Shares Out	n/a
EPS (ttm)	11.98
PE Ratio	27.31
Forward PE	19.75
Dividend	n/a
Ex-Dividend Date	n/a

Volume	81
Average Volume	28
Open	320.75
Previous Close	321.95
Day's Range	320.60 - 328.65
52-Week Range	313.80 - 487.50
Beta	n/a
RSI	42.52
Earnings Date	Nov 3, 2025

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The com...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1989
• Employees: 6,100
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: VRTX

Financial Performance

Financial numbers in USD